MARK4

Across TCGA pan-cancer cohorts, MARK4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MARK4 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MARK4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MARK4 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM and LSCC are the cancer types where MARK4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.905	0.582	<.001	13	view →
LSCC	OS	Median	All	0.918	0.795	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MARK4–GBM (DFS)

Open the GBM breakdown →